Date:
20130607
Docket:
T-689-11
Citation: 2013
FC 621
Ottawa, Ontario,
June 7, 2013
PRESENT: The
Honourable Mr. Justice Barnes
BETWEEN:
|
ELI LILLY CANADA INC.
|
|
|
Applicant
|
and
|
|
TEVA CANADA LIMITED AND
THE MINISTER OF HEALTH
|
|
|
Respondents
|
|
and
|
|
|
ELI LILLY AND COMPANY AND
TAKEDA PHARMACEUTICAL COMPANY LIMITED
|
|
|
|
Respondent Patentees
|
SUPPLEMENTARY REASONS FOR JUDGMENT
AND JUDGMENT
[1]
The
Applicant, Eli Lilly Canada Inc. (Lilly), seeks an Order for costs in
connection with the Court’s earlier dismissal of the its Patented Medicines
(Notice of Compliance) (NOC) application on the ground of mootness. In my
previous decision, I found that the application was moot because Teva Canada
Limited (Teva) had withdrawn its Notice of Allegation (NOA).
[2]
I
am satisfied that Lilly is entitled to an award of costs because Teva
affectively triggered this application by filing a NOA: see Eli Lilly
Canada Inc. v Novopharm, 2006 FC 781, [2006] FCJ no 1002. Lilly’s claim to
counsel fees of $18,803.00 and disbursements of $84,422.00 is, however,
excessive.
[3]
This
matter was resolved in its early stages and before any exchange of expert
evidence. An award under Column IV is, therefore, not justified. Costs under
Column III and reasonable disbursements up to the point of the withdrawal of
Teva’s NOA are appropriate subject to an offset of $2,000.00 for Teva’s costs
of successfully defending Lilly’s motion for a prohibition Order.
[4]
Notwithstanding
the early withdrawal of Teva’s NOA, it was prudent for Lilly to have retained
expert witnesses in advance of receiving Teva’s evidence. The time frames that
apply to NOC proceedings are tight and some anticipatory work with experts is
to be expected. However, I have nothing before me to justify a claim to expert
fees and expenses approaching $80,000.00. I have no idea how expert costs of
that magnitude could reasonably be generated before any reports were written.
I also have no explanation for why advance meetings with an expert witness in London and Ottawa were considered necessary. I will allow $12,500.00 for expert
costs including related disbursements.
JUDGMENT
THIS
COURT’S JUDGMENT is that Lilly will have its costs of this
application under Column III and its reasonable disbursements up to the point
of the withdrawal of Teva’s Notice of Allegation. This figure shall be reduced
by $2,000.00 representing Teva’s costs of successfully defending Lilly’s motion
for a prohibition Order.
THIS
COURT’S FURTHER JUDGMENT is that Lilly is entitled to recover $12,500.00
for its disbursements in connection with the retention of expert witnesses in
this proceeding.
"R.L.
Barnes"
FEDERAL COURT
SOLICITORS OF RECORD
DOCKET: T-689-11
STYLE OF CAUSE: ELI
LILLY CANADA INC. v TEVA CANADA LIMITED ET AL
PLACE OF HEARING: Ottawa, ON
DATE OF HEARING: January
8, 2013
REASONS FOR JUDGMENT: BARNES J.
DATED: June
7, 2013
APPEARANCES:
Anthony Creber and
Livia Aumand
|
FOR THE APPLICANT
AND
RESPONDENT PATENTEES
ELI LILLY CANADA
INC.
|
Jonathan Stainsby
|
FOR THE RESPONDENT
TEVA CANADA LIMITED
|
Christopher VanBarr
|
FOR THE RESPONDENT
PATENTEES
TAKEDA
PHARMACEUTICAL COMPANY LIMITED
|
SOLICITORS OF RECORD:
Gowling Lafleur Henderson LLP
Ottawa, ON
|
FOR THE APPLICANT
AND
RESPONDENT PATENTEES
ELI LILLY CANADA
INC.
|
Heenan Blaikie LLP
Toronto, ON
|
FOR THE RESPONDENT
TEVA CANADA LIMITED
|
William
F. Pentney
Deputy
Attorney General of Canada
Toronto, ON
|
FOR THE RESPONDENT
THE MINISTER OF
HEALTH
|
Gowling Lafleur Henderson LLP
Ottawa, ON
|
FOR THE RESPONDENT
PATENTEES
TAKEDA
PHARMACEUTICAL COMPANY
LIMITED
|